Class of Stock [Axis]
Series A Junior Participating Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Series G Convertible Preferred Stock [Member]
Equity Components [Axis]
Preferred Stock [Member]
Series G Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Statistical Measurement [Axis]
Minimum [Member]
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Warrant Exercise Inducement Offer Letter Agreement [Member]
Title and Position [Axis]
Investors [Member]
Sale of Stock [Axis]
Private Placement [Member]
Class of Warrant or Right [Axis]
Class I Warrants [Member]
Pre-Funded Warrants [Member]
Class J Warrants [Member]
Maximum [Member]
Intangible Asset, Finite-Lived, Class [Axis]
Patents [Member]
Trademarks [Member]
Note Purchase Agreement [Member]
Credit Facility [Axis]
Streeterville Capital LLC [Member]
Note 2 Purchase Agreement [Member]
Note 3 Purchase Agreement [Member]
Statement Of Income Location Balances [Axis]
Research And Development [Member]
General And Administrative [Member]
Product and Service [Axis]
Clinical Studies [Member]
Manufacturing and Engineering [Member]
Quality Control [Member]
Regulatory [Member]
Legal Entity [Axis]
Amarex Clinical Research LLC [Member]
Pancreatic Cancer [Member]
Post COVID Conditions [Member]
Sterling Pharma Solutions [Member]
Azenova Sales International [Member]
Alcami [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Sterling Proposal Agreement [Member]
Retirement Plan Name [Axis]
401(k) Plan [Member]
Plan Name [Axis]
2018 Equity Incentive Plan [Member]
Amended and Restated 2018 Equity Incentive Plan [Member]
Grantee Status [Axis]
Share-Based Payment Arrangement, Employee [Member]
Share-Based Payment Arrangement, Nonemployee [Member]
Securities Purchase Agreement [Member]
Class A Warrant [Member]
Class B Warrant [Member]
Class C and Class D Warrants [Member]
Class E Warrants [Member]
Class F Warrants [Member]
Class E And F Common Stock Purchase Warrants [Member]
2026 Rights Offering [Member]
G Warrants [Member]
Existing May 2024 Warrants [Member]
Class A and Class B Common Stock [Member]
Existing September 2024 Warrants [Member]
Class C and Class D Common Stock [Member]
Existing July 2025 Warrants [Member]
Class E and Class F Common Stock [Member]
Class H Warrants [Member]
Placement Agent Warrants [Member]
Ladenburg Thalmann & Co. Inc [Member]
Employee Stock Purchase Plan [Member]
Related and Nonrelated Parties [Axis]
Directors, Officers and Employees [Member]
Maxim Group LLC [Member]
Equity Distribution Agreement [Member]
Sales Agreement [Member]
Atlas Sciences LLC [Member]
Equity Purchase Agreement [Member]
Commitment Shares [Member]
Placement Agent [Member]
Class A Warrants [Member]
Class B Warrants [Member]
Class C Warrants [Member]
Class D Warrants [Member]
Class E and Class F Warrants [Member]
Purchase Agreement [Member]
Class G Warrants [Member]
Inducement Letter Agreements [Member]
Class F Warrant [Member]
Class H Warrant [Member]
Ladenburg Thalmann & Co. Inc. [Member]
Placement Agent Warrant [Member]
Class H Placement Agent Warrant [Member]
Holder-Side Consideration and Placement Agent Warrant [Member]
Holder-Side Inducement Consideration [Member]
May Class 2026 Class I Offering [Member]
Class I Common Stock Purchase Warrants [Member]
Class I Warrant [Member]
June 2026 Class J Offering [Member]
June 2026 Class J Offering [Member]
Antidilutive Securities [Axis]
Measurement Input Type [Axis]
Measurement Input, Exercise Price [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Share Price [Member]
Class C Warrant [Member]
Class D Warrant [Member]
Class E Warrant [Member]
Class G Warrant [Member]
Class I Warrant [Member]
Weighted Average [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Axis]
Unsecured Promissory Note [Member]
Unsecured Promissory Note One [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement [Table]
Statement [Line Items]
ASSETS
Current assets:
Cash and cash equivalents
Marketable investments
Other receivables
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Right of use asset, net
Patent and trademark rights, net
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable
Accrued expenses
Current portion of operating lease liability
Current portion of note payable, net
Total current liabilities
Long-term liabilities:
Operating lease liability
Long-term note payable
Warrant liability
Total liabilities
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Preferred Stock value
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 28,990,073 and 3,069,875 as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, stated value
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Clinical treatment programs - US
Total Revenues
Costs and Expenses:
Production costs
Research and development
General and administrative
Total Costs and Expenses
Operating loss
Gain (Loss) on investments
Interest and other income
Interest expense and other finance costs
Loss on change in fair value of warrant liability
Net Loss
Basic loss per share
Diluted loss per share
Weighted average shares outstanding basic
Weighted average shares outstanding diluted
Balance
Balance, shares
Common stock issuance, net of costs
Common stock issuance, net of costs, shares
Registered Direct Offering
Conversion of Series G Preferred Stock to Common Stock
Conversion of Series G Preferred Stock to Common Stock, shares
Warrant Exercise
Warrant exercise, shares
Reclass of Warrants E & F
Reclass of warrant E & F, shares
Repayment of Debt with Shares
Repayment of Debt with Shares, shares
Net comprehensive loss
Registered Direct Offering, shares
Issuance Costs
Equity-based compensation
Equity-based compensation, shares
Adjustment for fractional shares
Adjustment for fractional shares, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization
Abandonment and expiration of patents and trademark rights
Equity-based compensation
Gain on sale of marketable investments
Change in fair value of warrants
Loss on issuance of warrants
Change in assets and liabilities:
Prepaid expenses and other assets
Lease liability
Accounts payable and Accrued Expenses
Other receivables
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sale of marketable investments
Purchase of marketable investments
Purchase of patent and trademark rights
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs
Proceeds from note payable, net of issuance costs
Proceeds from warrant exercise
Repayment of debt obligation
Proceeds from Registered Direct Offerings
Proceeds from Rights Offering
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of non-cash investing and financing cash flow information:
Unrealized gain on marketable investments
Repayment of debt obligation with shares
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Type [Axis]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
Business and Basis of Presentation
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents
Investments, Debt and Equity Securities [Abstract]
Marketable Securities
Property, Plant, and Equipment [Abstract]
Property and Equipment, Net
Intangible Asset, Goodwill and Other [Abstract]
Patents and Trademark Rights, Net
Payables and Accruals [Abstract]
Accrued Expenses
Debt Disclosure [Abstract]
Unsecured Promissory Note
Leases
Leases
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements
Retirement Benefits [Abstract]
401(k) Plan
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation
Stock Warrants
Stock Warrants
Equity [Abstract]
Stockholders’ Equity
Earnings Per Share [Abstract]
Net Loss Per Share
Fair Value Disclosures [Abstract]
Fair Value
Subsequent Events [Abstract]
Subsequent Events
Schedule of Property and Equipment
Schedule of Patent and Trademark Rights
Schedule of Changes in Patents, Trademark Rights
Schedule of Amortization of Patents and Trademarks
Schedule of Accrued Expenses
Schedule of Long Term Debt
Schedule of Maturities of Long-Term Debt
Schedule of Interest and Other Charges
Schedule of AIM Recognized Rent Expense Associated with Operating Lease
Schedule of Operating Lease Future Payments
Schedule of Research and Development Expenses
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity
Schedule of Assumptions to Estimate Fair Value of Warrants
Schedule of Range of Probabilities
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Increase in stockholders equity
Share price
Reverse stock split
Previously billed fees
Exchange for payments
Common stock dividend payment ratio description
Warrants exercise price per share
Gross proceeds
Shares issued
Purchase of warrants
Stockholders' equity minimum requirement
Federally insured limit
Marketable securities held in mutual funds
Marketable securities held for sale
Net gain (loss) on equity securities
Unrealized gains recognized
Unrealized gains recognized
Recognized gain (loss)
Furniture, fixtures, and equipment
Less: accumulated depreciation
Property and equipment, net
Estimated useful life
Depreciation expense
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Gross carrying value
Accumulated amortization
Net carrying value
Beginning balance
Acquisitions
Abandonments and expirations
Amortization
Ending balance
2026
2027
2028
2029
2030
Thereafter
Total
Finite lived intangible assets, estimated useful life
Intangible assets, weighted remaining average amortization period
Compensation
Professional fees
Clinical trial expenses
Interest
Other expenses
Total
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Long-term debt
Unamortized Original issue discount
Unamortized Financing fees
Unamortized discount and debt issuance costs
Less current portion of long-term debt, net
Long-term debt, net
2026
2025
Total
Current portion of debt discount
Current portion of origination costs
2026
Line of Credit Facility [Table]
Line of Credit Facility [Line Items]
Interest
Original issue discount amortization
Total interest charges
Loan fee amortization
Exchange of unsecured promissory notes
Loan obligation settled
Long term debt
Debt issuance costs
Interest rate percentage
Redemption description
Shares issued for debt settlement
Extension fee
Principal amount
Original issue discount
Debt instrument periodic payment, principal
Lender transaction fees
Lessee, Lease, Description [Table]
Operating lease term
Operating lease Payment
Right of use asset
Lease liability
Accumulated amortization
Operating lease, remaining lease term
Weighted average remaining lease term
Weighted average incremental borrowing rate
Lease costs:
Operating lease costs
Short-term and variable lease costs
Total lease costs
Schedule Of Operating Lease Future Payments
2026
2027
Less imputed interest
Total
ResearchAndDevelopmentTable [Table]
Totals
Research and development expenses
Research and development expense
Research and development expense excluding acquired in process cost
Development cost
Invigilators cost
Manufacturing estimated costs
Retainer amount
Stock options, vested
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Percentage of maximum annual contribution per employee, as percentage of their annual salary
Deferred compensation arrangementl, cash awards granted, percentage
Contribution amount
Number of Options Outstanding, Beginning of Period
Weighted Average Exercise Price Outstanding, Beginning of Period
Weighted Average Remaining Contracted Term (years) Outstanding
Aggregate Intrinsic Value Outstanding, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value Outstanding, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options Outstanding, End of Period
Weighted Average Exercise Price Outstanding, End of Period
Weighted Average Remaining Contracted Term (years) Outstanding
Aggregate Intrinsic Value Outstanding, End of Period
Number of Options, Vested and Expected to Vest
Weighted Average Exercise Price, Vested and Expected to Vest
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest
Aggregate Intrinsic Value, Vested and Expected to Vest
Number of Options Exercisable, End of Period
Weighted Average Exercise Price Exercisable, End of Period
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period
Aggregate Intrinsic Value, End of Period
Unissued shares of common stock is reserved for potential issuance
Increase in common stock available for grant and issuance
Option term
Shares issued as compensation
Shares issued as compensation, value
Share based compensation expense
DisclosureStockWarrantsTable [Table]
Exercise price
Shares issued
Offering price per share
Stock dividends description
Change in fair value of warrant liability
Warrants from liability to equity
Shares issued
Preferred stock, stated value
Conversion price
Proceeds from issuance of units
Purchase of warrants percentage
Warrant exercise term
Cash fee
Cash fee percentage
Offering expenses
Management fee
Gross proceeds of warrants percentage
Exercise price percentage
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Common stock, stated value
Standard blocker
Maximum Blocker
Registered shares of common stock
Warrant to purchase shares of common stock
Exercisable
Expiration date of issuance
Preferred stock shares outstanding
Convertible, shares issuable
Conversion of shares
Preferred stock shares issued
Common stock specific limitations and restrictions on usage
Common stock shares issued, value
Issuance of common stock
Aggregate gross proceeds, percentage
Reimbursement expenses
Number of shares sold
Value of shares sold
Market price, percentage
Trading maximum lessor amount
Beneficial ownership percentage
Commitment shares issued
Warrants term description
Proceeds from warrants
Warrant exercised
Gross proceeds from transactions
Offering price
Reimbursement expenses
Change of warrant liabilities
Fair value adjustment of warrants
Gross proceeds
Cash fees
Increase decrease in stockholders equity
Cash commission percentage
Cash commission
Managemment fee percentage
Management fee
Reimbursement expenses
Offering price percentage
Unregistered shares
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants, shares
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share
Expected dividend yield
Expected holding period
Underlying price per share
Percentage of probability
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure
Marketable securities
Fair value measurement, input percentage
Subsequent Event [Table]
Subsequent Event [Line Items]
Preferred Stock, Convertible, Shares Issuable
Conversion of Stock, Shares Converted
Preferred Stock, Shares Outstanding
Outstanding shares percentage
Number of shares of the common stock available for grant and issuance
Special meeting description
Number of outstanding shares requirement for representing at the meeting
Number of common shares redeemed
Common shares redemption price
Series A Junior Participating Preferred Stock [Member]
Preferred stock stated value per share.
Series B Convertible Preferred Stock [Member]
Series G Convertible Preferred Stock [Member]
Loss on issuance of warrants.
Stock issued during period value warrants exercised.
Stock issued during period shares warrants exercised.
Stock issued during reclass of warrants value.
Stock issued during reclass of warrants shares.
Stock issued during period value repayment of debt.
Stock issued during period shares repayment of debt.
Stock issued during period value adjustment for fractional shares.
Stock issued during period shares adjustment for fractional shares.
Unrealized gain loss on marketable investments.
Repayment of debt obligation with shares.
Proceeds from registered direct offerings.
Common stock dividend payment ratio description.
Warrant Exercise Inducement Offer Letter Agreement [Member]
Investors [Member]
Class I Warrants [Member]
Class J Warrants [Member]
Finite lived intangible assets abandonments.
Finite lived intangible assets amortization expense after year four.
Accrued clinical trial expenses current.
Note Purchase Agreement [Member]
Streeterville Capital LLC [Member]
Extension fee.
Note 2 Purchase Agreement [Member]
Note 3 Purchase Agreement [Member]
2026 Rights Offering [Member]
Common stock stated value per share.
Share price trigger percentage.
Maximum threshold percentage.
G Warrants [Member]
Proceeds from issuance of units.
Class of warrant or right term.
Common stock shares with limitations and restrictions on usage.
Employee Stock Purchase Plan [Member]
Directors, Officers and Employees [Member]
Maxim Group LLC [Member]
Equity Distribution Agreement [Member]
Sales Agreement [Member]
Schedule Of Interest And Other Charges [Table Text Block]
Atlas Sciences LLC [Member]
Equity Purchase Agreement [Member]
Market price, percentage.
Beneficial ownership percentage.
Stock issued during period value commitment shares.
Commitment Shares [Member]
Securities Purchase Agreement [Member]
Class A Warrant [Member]
Class B Warrant [Member]
Warrants and rights outstanding term description.
Placement Agent [Member]
Class C and Class D Warrants [Member]
Class E Warrants [Member]
Class F Warrants [Member]
Stock dividends description.
Operation lease right of use asset accumulated amortization.
Class E And F Common Stock Purchase Warrants [Member]
Change in fair value of warrant liability.
Warrants from liability to equity.
Research Consulting And Supply Agreements [Text Block]
Schedule Of Research and Development Expenses [Table Text Block]
Amarex Clinical Research LLC [Member]
Retainer amount.
Azenova Sales International [Member]
Alcami [Member]
Preferred stock preferred stock stated value per share.
Class G Warrants [Member]
401(k) Plan [Member]
2018 Equity Incentive Plan [Member]
Stock issued during period shares stock warrant exercised.
Amended and Restated 2018 Equity Incentive Plan [Member]
Inducement Letter Agreements [Member]
Class F Warrant [Member]
Class H Warrant [Member]
Share-based compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.
Aggregate intrinsic value, granted.
Aggregate intrinsic value, forfeited.
ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value
Ladenburg Thalmann & Co. Inc. [Member]
Underlying price per share.
Class I Warrant [Member]
Stock Warrants [Disclosure Text Block]
Fair value measurement input percentage.
Schedule Of Range Of Probabilities [Table Text Block]
Percentage of probability.
Pre-Funded Warrants [Member]
Existing May 2024 Warrants [Member]
Class A and Class B Common Stock [Member]
Existing September 2024 Warrants [Member]
Existing July 2025 Warrants [Member]
Class C and Class D Common Stock [Member]
Class E and Class F Common Stock [Member]
Class H Pacement Agent Warrants [Member]
Purchase of warrants percentage.
Strike price.
Class H Warrants [Member]
Warrant exercise term.
Placement Agent Warrants [Member]
Ladenburg Thalmann & Co. Inc [Member]
May Class 2026 Class I Offering [Member]
Gross proceeds of warrants percentage.
Class I Common Stock Purchase Warrants [Member]
Cash fee percentage.
Exercise price percentage.
Cash commission percentage.
Commission fees.
Reimbursement expenses.
Offering price percentage.
Class I Warrant [Member]
June 2026 Class J Offering [Member]
Unregistered shares of common stock.
Class C Warrant [Member]
Class D Warrant [Member]
Class E Warrant [Member]
Class G Warrant [Member]
Number of outstanding shares requirement for representing at the meeting.
Outstanding shares percentage.
Clinical Studies [Member]
Manufacturing and Engineering [Member]
Quality Control [Member]
Regulatory [Member]
Pancreatic Cancer [Member]
Post COVID Conditions [Member]
Sterling Pharma Solutions [Member]
Statement Of Income Location Balances [Axis]
Research And Development [Member]
General And Administrative [Member]
Trading daily maximum lessor amount.
Dividend [Member]
Research and development expense including production cost adjustment.
Class C Warrants [Member]
Class D Warrants [Member]
Class A Warrants [Member]
Class B Warrants [Member]
Purchase Agreement [Member]
Class E and Class F Warrants [Member]
Sterling Proposal Agreement [Member]
Unsecured Promissory Note [Member]
Unsecured Promissory Note One [Member]
Placement Agent Warrant [Member]
Class H Placement Agent Warrant [Member]
Holder-Side Consideration and Placement Agent Warrant [Member]
Holder-Side Inducement Consideration [Member]
June2026ClassJOfferingMember
Class I Warrant [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Liabilities and Equity
Revenues
Costs and Expenses
Operating Income (Loss)
Shares, Outstanding
StockIssuedDuringPeriodSharesAdjustmentForFractionalShares
Share-Based Payment Arrangement, Noncash Expense
Marketable Security, Unrealized Gain (Loss)
Gain (Loss) on Sale of Derivatives
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Receivables
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Investments
Payments to Acquire Intangible Assets
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Repayments of Debt and Lease Obligation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Lessee, Operating Leases [Text Block]
Stock Warrants [Disclosure Text Block]
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
FinitelivedIntangibleAssetsAbandonments
Intangible Asset, Finite-Lived, Amortization Expense
Debt Issuance Costs, Net
Long-Term Debt, Current Maturities
Long-Term Debt, Maturity, Remainder of Fiscal Year
Long-Term Debt, Maturity, Year Two
Interest Expense, Debt, Excluding Amortization
Operating Lease, Liability
OperationLeaseRightOfUseAssetAccumulatedAmortization
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
ChangeInFairValueOfWarrantLiability
Shares, Issued
PreferredStockPreferredStockStatedValuePerShare
Management Fee Expense